Loading
Life sciences · Journal article
Materials Today Advances · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Nanomedicine is a promising strategy for cancer therapy. However, the low delivery efficiency of nanoparticles (NPs) to tumors remains a challenge and hinders clinical translation. In this study, an artificial intelligence (AI)-assisted physiologically based pharmacokinetic (PBPK) model was developed to predict NPs' tumor delivery efficiency (DE) based on the physicochemical properties and experimental strategies. First, a generic PBPK model was applied to describe NPs’ tumor kinetics, and six different tumor-related parameters were determined. Second, machine learning (ML) and AI models were developed for predicting the tumor-related parameters. Incorporating the ML-predicted parameters into the PBPK model, an ML-assisted PBPK model was developed to predict the tumor kinetics of NPs. This generic PBPK model was applied to simulate the tumor kinetics, in which 114 out of 152 datasets (75%) achieved the determination coefficient (R 2 ) of ≥0.75, and the overall R 2 was 0.92. Distribution (PT) and permeability (PATC) coefficients at the tumor site were the most important parameters in predicting tumor DEs. The deep neural network (DNN) model was the best-performing model and selected for tumor-related parameter estimations. Targeting strategy and surface charge were determined as the important features for predicting various tumor-related PBPK parameters. External validation was conducted using an in vivo experiment, and half of the predicted concentrations were within the two-fold error of the observed data. This model can serve as a complementary tool for predicting tumor kinetics prior to animal experimentation, helping identify promising NP formulations and potentially improving the success rate of drug delivery.